MX2024006105A - Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme. - Google Patents

Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme.

Info

Publication number
MX2024006105A
MX2024006105A MX2024006105A MX2024006105A MX2024006105A MX 2024006105 A MX2024006105 A MX 2024006105A MX 2024006105 A MX2024006105 A MX 2024006105A MX 2024006105 A MX2024006105 A MX 2024006105A MX 2024006105 A MX2024006105 A MX 2024006105A
Authority
MX
Mexico
Prior art keywords
nitroxoline
prevention
treatment
plexiform neurofibroma
plexiform
Prior art date
Application number
MX2024006105A
Other languages
English (en)
Spanish (es)
Inventor
David Brown
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of MX2024006105A publication Critical patent/MX2024006105A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024006105A 2021-11-19 2022-11-18 Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme. MX2024006105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2116743.2A GB202116743D0 (en) 2021-11-19 2021-11-19 Treatment
PCT/GB2022/052933 WO2023089328A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma

Publications (1)

Publication Number Publication Date
MX2024006105A true MX2024006105A (es) 2024-05-30

Family

ID=79163954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006105A MX2024006105A (es) 2021-11-19 2022-11-18 Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme.

Country Status (11)

Country Link
US (1) US20250000852A1 (enExample)
EP (1) EP4433054B1 (enExample)
JP (1) JP2024540439A (enExample)
KR (1) KR20240108407A (enExample)
CN (1) CN118215479A (enExample)
AU (1) AU2022392456A1 (enExample)
CA (1) CA3238805A1 (enExample)
GB (1) GB202116743D0 (enExample)
IL (1) IL312885A (enExample)
MX (1) MX2024006105A (enExample)
WO (1) WO2023089328A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment
WO2026022492A1 (en) * 2024-07-26 2026-01-29 Healx Limited Nitroxoline for use in the treatment and/or prevention of pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239149B (zh) * 2008-10-06 2015-05-13 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
GB202108224D0 (en) * 2021-06-09 2021-07-21 Healx Ltd Treatment

Also Published As

Publication number Publication date
IL312885A (en) 2024-07-01
CA3238805A1 (en) 2023-05-25
CN118215479A (zh) 2024-06-18
EP4433054B1 (en) 2026-07-08
JP2024540439A (ja) 2024-10-31
EP4433054A1 (en) 2024-09-25
AU2022392456A1 (en) 2024-05-23
WO2023089328A1 (en) 2023-05-25
KR20240108407A (ko) 2024-07-09
GB202116743D0 (en) 2022-01-05
US20250000852A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
MX2025009723A (es) Metodos de tratamiento contra adicciones
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
PH12021550368A1 (en) Dimethyl amino azetidine amides as jak inhibitors
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
MY202884A (en) Compounds useful in hiv therapy
PH12021551873A1 (en) Hydroxypyridoxazepines as nrf2 activators
MX2024004725A (es) Metodos novedosos.
WO2021089768A3 (en) Treatment and prevention of a neurodegenerative disorder
PH12020551117A1 (en) Compositions for preventing or treating uveitis
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
PH12019550138A1 (en) Pharmaceutical combinations for treating cancer
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
ZA202204442B (en) Salt forms of a complement component c5a receptor
MX2023014530A (es) Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo.
MX2021005944A (es) Inhibidores de rip1.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MY205944A (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.